Equities research analysts at StockNews.com started coverage on shares of OpGen (NASDAQ:OPGN – Get Free Report) in a report issued on Sunday. The firm set a “sell” rating on the medical research company’s stock.
OpGen Stock Performance
OPGN opened at $3.04 on Friday. The business has a 50 day moving average price of $2.86 and a 200 day moving average price of $4.19. OpGen has a twelve month low of $1.65 and a twelve month high of $38.40.
OpGen (NASDAQ:OPGN – Get Free Report) last issued its quarterly earnings results on Monday, July 8th. The medical research company reported $0.21 EPS for the quarter. The company had revenue of $0.17 million for the quarter. OpGen had a negative return on equity of 1,827.76% and a negative net margin of 997.34%.
Institutional Inflows and Outflows
OpGen Company Profile
OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.
Recommended Stories
- Five stocks we like better than OpGen
- How Can Investors Benefit From After-Hours Trading
- Survey: Top 175 Fittest Retirement Locations in America
- How to Invest in the FAANG Stocks
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- Golden Cross Stocks: Pattern, Examples and Charts
- Leading Gold Stock Shines With Q2 2024 Earnings Release
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.